Press release
HER2-Positive Breast Cancer Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Key Companies - Genentech, Shanghai PerHum Therapeutics Co., Ltd., ALX Oncology, Zy
"HER2-Positive Breast Cancer Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the HER2-Positive Breast Cancer Market.
The HER2-Positive Breast Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the HER2-Positive Breast Cancer Pipeline Report: https://www.delveinsight.com/report-store/her2-positive-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel HER2-Positive Breast Cancer treatment therapies with a considerable amount of success over the years.
• HER2-Positive Breast Cancer companies working in the treatment market are AdaptVac, Voronoi, Dizal Pharmaceuticals, Alteogen, Inc., Precirix, BioInvent International, Shanghai Miracogen Inc., Jiangsu Alphamab BioPharmaceuticals, CSPC ZhongQi Pharmaceutical Technology, Jiangsu HengRui Medicine Co., Ltd., Shanghai Henlius Biotech, and others, are developing therapies for the HER2-Positive Breast Cancer treatment
• Emerging HER2-Positive Breast Cancer therapies such as - ES2B C001, VRN 10, DZD1516, ALT-P7, CAM-H2, BI-1607+ trastuzumab, MRG002, KN-026, DP 303c, SHR-A1811, HLX11, and others are expected to have a significant impact on the HER2-Positive Breast Cancer market in the coming years.
• In July 2022, A Phase III, Multicenter, Randomised, Open-Label, Parallel Controlled Study of SHR-A1811 Versus Pyrotinib in Combination With Capecitabine forHER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane was started by Jiangsu HengRui Medicine Co., Ltd.'
• In May 2022, An open, multicenter Ib/II Phase Study of SHR-A1811 Plus Pyrrodinib or Ptutuzumab or SHR-1316 or Albumin Paclitaxel in the Treatment of HER2 PositiveNon Resectable or Metastatic Breast Cancer was started by Jiangsu HengRui Medicine Co., Ltd. SHR-A1811 coupled with pyrrolidone, patrozumab, SHR-1316, or albumin paclitaxel should be tested for safety, tolerability, and effectiveness in patients with HER2 positive non-resectable or metastatic breast cancer
• In July 2020, The National Medical Products Administration approved and issued the "Drug Clinical Trial Approval Notice" to Hengrui Pharmaceuticals, approving the company's novel drug SHR-A1811 for injection to conduct clinical trials for the treatment of advanced solid tumours with HER2 expression or mutation
HER2-Positive Breast Cancer Overview
HER2-positive The second most common cancer worldwide and the one that is most frequently diagnosed in women is breast cancer. HER2-positive breast tumours make up about 1 in 5 cases. HER2-positive breast cancers are more aggressive than other types of breast cancer. A protein called HER2 promotes rapid cell growth in breast cancer.
Get a Free Sample PDF Report to know more about HER2-Positive Breast Cancer Pipeline Therapeutic Assessment-
https://www.delveinsight.com/sample-request/her2-positive-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging HER2-Positive Breast Cancer Drugs Under Different Phases of Clinical Development Include:
• ES2B C001: AdaptVac
• VRN 10: Voronoi
• ALT P7: Alteogen
• ARX 788: Ambrx
• DZD1516: Dizal Pharmaceuticals
• ALT-P7: Alteogen, Inc.
• Inavolisib: Genentech
• CAM-H2: Precirix
• BI-1607+ trastuzumab: BioInvent International
• MRG002: Shanghai Miracogen Inc.
• KN-026: Jiangsu Alphamab BioPharmaceuticals
• DP 303c: CSPC ZhongQi Pharmaceutical Technology
• SHR-A1811: Jiangsu HengRui Medicine Co., Ltd.
• HLX11: Shanghai Henlius Biotech
Route of Administration
HER2-Positive Breast Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Molecule Type
Products have been categorized under various Molecule types, such as
• Oligonucleotide
• Peptide
• Small molecule
HER2-Positive Breast Cancer Pipeline Therapeutics Assessment
• HER2-Positive Breast Cancer Assessment by Product Type
• HER2-Positive Breast Cancer By Stage and Product Type
• HER2-Positive Breast Cancer Assessment by Route of Administration
• HER2-Positive Breast Cancer By Stage and Route of Administration
• HER2-Positive Breast Cancer Assessment by Molecule Type
• HER2-Positive Breast Cancer by Stage and Molecule Type
DelveInsight's HER2-Positive Breast Cancer Report covers around 75+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further HER2-Positive Breast Cancer product details are provided in the report. Download the HER2-Positive Breast Cancer pipeline report to learn more about the emerging HER2-Positive Breast Cancer therapies at:
https://www.delveinsight.com/sample-request/her2-positive-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the HER2-Positive Breast Cancer Therapeutics Market include:
Key companies developing therapies for HER2-Positive Breast Cancer are - Genentech, Shanghai PerHum Therapeutics Co., Ltd., ALX Oncology, Zymeworks Inc., Daiichi Sankyo, Byondis, Alphamab Oncology, Artiva Biotherapeutics, Celltrion, Levena Biopharma, Shanghai Miracogen Inc., Roche Pharma AG, Dizal Pharmaceuticals, Greenwich LifeSciences, Zymeworks Inc., Pieris Pharmaceuticals, Inc., Orum Therapeutics, RemeGen Co., Ltd., Mersana Therapeutics, Ambrx, Alteogen, Suzhou Zanrong Pharma Limited, AstraZeneca, Shanghai Henlius Biotech, GeneQuantum Healthcare (Suzhou) Co., Ltd., Klus Pharma Inc., Carisma Therapeutics Inc, Triumvira Immunologics, Inc., Precirix, Seagen Inc., CSPC ZhongQi Pharmaceutical Technology Co., Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Sichuan Baili Pharmaceutical Co., Ltd., Tianjin Hemay Biotech, Precirix, Zymeworks Inc., Menarini Group, Cadila Healthcare Limited, Merus N.V., and others.
HER2-Positive Breast Cancer Pipeline Analysis:
The HER2-Positive Breast Cancer pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of HER2-Positive Breast Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for HER2-Positive Breast Cancer Treatment.
• HER2-Positive Breast Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• HER2-Positive Breast Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the HER2-Positive Breast Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about HER2-Positive Breast Cancer drugs and therapies-
https://www.delveinsight.com/sample-request/her2-positive-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
HER2-Positive Breast Cancer Pipeline Market Drivers
• Increase in prevalence of Breast Cancer and its recurrence, robust Pipeline, higher Indulgence of Immunotherapy are some of the important factors that are fueling the HER2-Positive Breast Cancer Market.
HER2-Positive Breast Cancer Pipeline Market Barriers
• However, side effects associated with the treatment, high cost of the treatment and other factors are creating obstacles in the HER2-Positive Breast Cancer Market growth.
Scope of HER2-Positive Breast Cancer Pipeline Drug Insight
• Coverage: Global
• Key HER2-Positive Breast Cancer Companies: AdaptVac, Voronoi, Dizal Pharmaceuticals, Alteogen, Inc., Precirix, BioInvent International, Shanghai Miracogen Inc., Jiangsu Alphamab BioPharmaceuticals, CSPC ZhongQi Pharmaceutical Technology, Jiangsu HengRui Medicine Co., Ltd., Shanghai Henlius Biotech, and others
• Key HER2-Positive Breast Cancer Therapies: ES2B C001, VRN 10, DZD1516, ALT-P7, CAM-H2, BI-1607+ trastuzumab, MRG002, KN-026, DP 303c, SHR-A1811, HLX11, and others
• HER2-Positive Breast Cancer Therapeutic Assessment: HER2-Positive Breast Cancer current marketed and HER2-Positive Breast Cancer emerging therapies
• HER2-Positive Breast Cancer Market Dynamics: HER2-Positive Breast Cancer market drivers and HER2-Positive Breast Cancer market barriers
Request for Sample PDF Report for HER2-Positive Breast Cancer Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/her2-positive-breast-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 HER2-Positive Breast Cancer Report Introduction
2 HER2-Positive Breast Cancer Executive Summary
3 HER2-Positive Breast Cancer Overview
4 HER2-Positive Breast Cancer- Analytical Perspective In-depth Commercial Assessment
5 HER2-Positive Breast Cancer Pipeline Therapeutics
6 HER2-Positive Breast Cancer Late Stage Products (Phase II/III)
7 HER2-Positive Breast Cancer Mid Stage Products (Phase II)
8 HER2-Positive Breast Cancer Early Stage Products (Phase I)
9 HER2-Positive Breast Cancer Preclinical Stage Products
10 HER2-Positive Breast Cancer Therapeutics Assessment
11 HER2-Positive Breast Cancer Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 HER2-Positive Breast Cancer Key Companies
14 HER2-Positive Breast Cancer Key Products
15 HER2-Positive Breast Cancer Unmet Needs
16 HER2-Positive Breast Cancer Market Drivers and Barriers
17 HER2-Positive Breast Cancer Future Perspectives and Conclusion
18 HER2-Positive Breast Cancer Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Related Reports:
HER2-Positive Breast Cancer Market
https://www.delveinsight.com/report-store/her2-positive-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'HER2-Positive Breast Cancer-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
HER2-Positive Breast Cancer Epidemiology
https://www.delveinsight.com/report-store/her2-positive-breast-cancer-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'HER2-Positive Breast Cancer Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.
Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.
Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HER2-Positive Breast Cancer Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Key Companies - Genentech, Shanghai PerHum Therapeutics Co., Ltd., ALX Oncology, Zy here
News-ID: 3051898 • Views: …
More Releases from DelveInsight Business Research
Spasticity Clinical Pipeline 2025: A Comprehensive Review of 12+ Emerging Therap …
According to DelveInsight's latest analysis, the global Spasticity pipeline features more than 10 active pharmaceutical companies that are advancing over 12 investigational therapies. The report offers a detailed evaluation of clinical trials, mechanisms of action, therapeutic approaches, routes of administration, and major developmental activities shaping the Spasticity treatment landscape.
DelveInsight's report, "Spasticity Pipeline Insight, 2025," delivers an extensive overview of the current clinical development environment and the future outlook for the…
Real-World Evidence Solution Market is set to grow at a 8.07% CAGR, reaching USD …
According to DelveInsight, the real-world evidence (RWE) solutions market is expanding rapidly, primarily due to the increasing global burden of chronic diseases and the growing need to improve healthcare outcomes. In addition, advancements in big data analytics, artificial intelligence, and machine learning are enhancing the ability to efficiently process and interpret large-scale real-world datasets. The rising adoption of RWE solutions by pharmaceutical and biotechnology companies - to support drug development,…
Spinal Implants Market is set to grow at a 5.50% CAGR, reaching USD 21.9 billion …
According to DelveInsight's assessment, the rising burden of spinal disorders particularly within the growing elderly population - continues to significantly increase the demand for surgical correction procedures. Alongside this, the surge in sports-related injuries and trauma cases is accelerating the need for advanced implantable spinal solutions. There is also a notable shift toward non-fusion and motion-preserving devices that support spinal flexibility and enhance patient outcomes, especially for younger and more…
Vascular Stents Market is set to grow at a 6.65% CAGR, reaching USD 18.28 billio …
According to DelveInsight's assessment, the rising global burden of cancer is significantly increasing the demand for advanced treatment approaches such as tumor ablation. Minimally invasive ablation techniques are gaining strong traction due to their advantages, including faster recovery times, lower complication risks, and reduced costs compared with traditional surgical procedures. At the same time, continuous improvements in ablation technologies - particularly in radiofrequency, microwave, and cryoablation systems - have enhanced…
More Releases for HER2
HER2-Positive Breast Cancer (HER2+ BC) Clinical Market to Reach USD 21.46 Billio …
Sub-Headline: The global HER2-Positive Breast Cancer Clinical Market is expected to rise from USD 13.82 billion in 2023 to USD 21.46 billion by 2030, registering a CAGR of 6.5%, driven by rapid uptake of antibody-drug conjugates (ADCs), dual-targeted therapies, and AI-enabled precision oncology diagnostics.
Introduction
The HER2-Positive Breast Cancer (HER2+ BC) Clinical Market is undergoing a major transformation fueled by next-generation targeted therapies, breakthrough ADCs, biosimilar expansion, and genomic testing advancements. HER2+…
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
